FDA Approves Mylan’s Biosimilar of HUMIRA (Adalimumab)

Goodwin
Contact

Goodwin

On July 6, 2020, the U.S. FDA approved Mylan’s aBLA for HULIO (adalimumab-fkjp), a biosimilar of AbbVie’s HUMIRA. HULIO is indicated for treating certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. HUMIRA, in contrast, is additionally approved for the treatment of certain patients with pediatric Crohn’s disease, hidradenitis suppurativa, and uveitis.

HULIO is the sixth biosimilar of HUMIRA to obtain FDA-approval, following Amgen’s AMJEVITA (adalimumab-atto) in September 2016, Boehringer Ingelheim’s CYLTEZO (adalimumab-adbm) in August 2017, Sandoz’s HYRIMOZ (adalimumab-adaz) in October 2018, Samsung Bioepis’s HADLIMA (adalimumab-bwwd) in July 2019, and Pfizer’s ABRILADA (adalimumab-afzb) in November 2019. None of these biosimilars are yet on the U.S. market, however, as each biosimilar applicant has entered into a license agreement with AbbVie that permits the applicant to begin U.S. marketing only after a specified date in 2023. As we previously reported, AbbVie has granted the following U.S. license dates:

  1. Amgen: January 31, 2023
  2. Samsung Bioepis: June 30, 2023
  3. Boehringer Ingelheim: July 1, 2023
  4. Mylan: July 31, 2023
  5. Fresenius Kabi: September 30, 2023
  6. Sandoz: September 30, 2023
  7. Momenta: November 20, 2023
  8. Pfizer: November 20, 2023
  9. Coherus: December 15, 2023

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.